RET-fusion positive solid tumor

A RET-fusion positive solid tumor is a biomarker-defined malignant neoplasm characterized by an oncogenic rearrangement involving the rearranged during transfection (*RET*) proto-oncogene As a tissue-agnostic oncologic entity, it can emerge in diverse anatomical sites—most commonly non-small cell lung and thyroid cancers, but also gastrointestinal, breast, and gynecologic malignancies—across both pediatric and adult populations Clinically, these tumors behave as primary oncogenic drivers, and th...

A RET-fusion positive solid tumor is a biomarker-defined malignant neoplasm characterized by an oncogenic rearrangement involving the rearranged during transfection (*RET*) proto-oncogene This molecular abnormality arises from genomic translocations or inversions that join the 3′ kinase domain of *RET* to a 5′ partner gene, resulting in ligand-independent dimerization and constitutive activation of downstream MAPK and PI3K/AKT proliferation signaling cascades As a tissue-agnostic oncologic entit...

This molecular abnormality arises from genomic translocations or inversions that join the 3′ kinase domain of *RET* to a 5′ partner gene, resulting in ligand-independent dimerization and constitutive activation of downstream MAPK and PI3K/AKT proliferation signaling cascades

As a tissue-agnostic oncologic entity, it can emerge in diverse anatomical sites—most commonly non-small cell lung and thyroid cancers, but also gastrointestinal, breast, and gynecologic malignancies—across both pediatric and adult populations Clinically, these tumors behave as primary oncogenic drivers, and therapeutic targeting is generally indicated for locally advanced or metastatic presentations requiring systemic therapy

As a tissue-agnostic oncologic entity, it can emerge in diverse anatomical sites—most commonly non-small cell lung and thyroid cancers, but also gastrointestinal, breast, and gynecologic malignancies—across both pediatric and adult populations

Clinically, these tumors behave as primary oncogenic drivers, and therapeutic targeting is generally indicated for locally advanced or metastatic presentations requiring systemic therapy